to our Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission ("SEC") on

Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

AVIV, Israel, November 26, 2025 /PRNewswire/ -Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"),

a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, reports financial

results for the three and nine months ended September 30, 2025 and recent developments.

Summary - Third Quarter 2025 vs. Third Quarter 2024

Galmed Pharmaceuticals Ltd.

are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for

the treatment of liver disease and we are currently seeking to advance the development of Aramchol for oncological indications outside

of NASH and fibrosis. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our

product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core

expertise in drug development.

statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking

statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could

cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors

could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements,

including, but not limited to, the development and approval of the use of Aramchol or any other product candidate for indications outside

of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in

combination therapy; the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop;

completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other

product candidate by the U.S. Food and Drug Administration or the European Medicines Authority, including but not limited to acceptance

of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication

and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable

post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product;

our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol,

or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market

adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch

of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the

possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates

in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution

channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development,

regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding

licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments

with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The

Nasdaq Capital Market; the security, political and economic instability in the Middle East that could harm our business, including due

to the current security situation in Israel, risks relating to our digital asset management strategy, including the highly volatile nature

of the price of cryptocurrencies and other digital assets, the risk that our share price may be highly correlated to the price of the

cryptocurrencies and other digital assets that we may hold, risks related to increased competition in the industries in which we do and

will operate, risks relating to significant legal, commercial, regulatory and technical uncertainty regarding cryptocurrencies and other

digital assets generally, risks relating to the treatment of crypto assets for U.S. and foreign tax purposes and those risks and uncertainties

identified in Exhibit 99.2 to our Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission ("SEC")

on August 25, 2025. We believe these forward-looking statements are reasonable; however, these statements are only current predictions

and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels

of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss

many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 2, 2025 in greater

detail under the heading "Risk Factors." Given these uncertainties, you should not rely upon forward-looking statements as

predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the

date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations

to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence

of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

PHARMACEUTICALS LTD.

Dollars in thousands, except share data and per share data

PHARMACEUTICALS LTD.

Statements of Operations (Unaudited)

Dollars in thousands, except share data and per share data

PHARMACEUTICALS LTD.

Statements of Cash Flows (Unaudited)

Dollars in thousands

Pharmaceuticals Ltd.,

investor.relations@galmedpharma.com,